IVI To Speed Development Of MERS Vaccines
This article was originally published in PharmAsia News
In a move that will speed up work in the area, the International Vaccine Institute (IVI) is to launch a project for the research and development of vaccines for Middle East Respiratory Syndrome (MERS) with financial support from South Korea’s Samsung Medical Center. The institute is in the process of selecting collaborators that have data suggesting protection in animal models.
You may also be interested in...
US FDA defers action on Spectrum’s approval application for neutropenia candidate Rolontis due to pandemic-related difficulties inspecting partner Hanmi’s plant. The action date has been put back by around four months although the companies stress no CRL has been issued.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.